| Lower-risk antibodies | anti-NMDAR (except in teratoma), anti-LGI1, anti-GABA-B |
| Anti-Yo (PCA-1) | Most common; associated with ovarian cancer and breast cancer. Targets cerebellar degeneration-related protein 2 (CDR2) and CDR2L in Purkinje cells |
| Anti-Tr/DNER | Associated with Hodgkin lymphoma. Targets Delta/Notch-like EGF-related receptor on Purkinje cells |
| Anti-Hu (ANNA-1) | Associated with small cell lung cancer (SCLC). Usually presents as part of multifocal encephalomyelitis with cerebellar involvement |
| Anti-VGCC | Associated with SCLC, often co-occurring with Lambert-Eaton syndrome |
| Anti-mGluR1 | Associated with Hodgkin lymphoma |
| Anti-Hu | SCLC (most common paraneoplastic cause of limbic encephalitis) |
| Anti-Ma2 | Testicular germ cell tumors (young males), lung cancer (older patients) |
| Anti-AMPAR | Breast, lung, thymic tumors |
| Anti-GABA-B | SCLC |
| Anti-CASPR2 | Thymoma (also occurs without cancer) |
| Databases | OMIMOrphanetClinicalTrialsPubMed |
No AI portrait yet
No comments yet. Be the first to comment!